Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Published byNeal Thomas Modified over 9 years ago

Similar presentations

Presentation on theme: "Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone."— Presentation transcript:

1 Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone receptor- negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance) Presented By Halle Moore at 2014 ASCO Annual Meeting

2 Background Presented By Halle Moore at 2014 ASCO Annual Meeting

3 Ovarian Protection with LHRH analog Presented By Halle Moore at 2014 ASCO Annual Meeting

4 POEMS/S0230 Schema Presented By Halle Moore at 2014 ASCO Annual Meeting

5 POEMS Objectives and Endpoints Presented By Halle Moore at 2014 ASCO Annual Meeting

6 Goserelin Administration Presented By Halle Moore at 2014 ASCO Annual Meeting

7 Patient Eligibility Presented By Halle Moore at 2014 ASCO Annual Meeting

8 Statistical Considerations Presented By Halle Moore at 2014 ASCO Annual Meeting

9 POEMS Consort Diagram Presented By Halle Moore at 2014 ASCO Annual Meeting

10 Patients Presented By Halle Moore at 2014 ASCO Annual Meeting

11 Endocrine Toxicity Presented By Halle Moore at 2014 ASCO Annual Meeting

12 POEMS Ovarian Failure Presented By Halle Moore at 2014 ASCO Annual Meeting

13 POEMS Secondary Ovarian Outcomes Presented By Halle Moore at 2014 ASCO Annual Meeting

14 POEMS Pregnancy Presented By Halle Moore at 2014 ASCO Annual Meeting

15 POEMS Disease Free Survival Presented By Halle Moore at 2014 ASCO Annual Meeting

16 POEMS Overall Survival Presented By Halle Moore at 2014 ASCO Annual Meeting

17 POEMS Presented By Halle Moore at 2014 ASCO Annual Meeting

18 Conclusions Presented By Halle Moore at 2014 ASCO Annual Meeting

19 Acknowledgements Presented By Halle Moore at 2014 ASCO Annual Meeting

Download ppt "Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone."

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer

Integration of Taxanes in the Management of Breast Cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.

1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.

Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.

Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C.

Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C.

Similar presentations

Ads by Google